MD1 Stock Overview
Develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Medistim ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 13.00 |
| 52 Week High | NOK 20.10 |
| 52 Week Low | NOK 11.10 |
| Beta | 0.99 |
| 1 Month Change | 3.17% |
| 3 Month Change | -15.86% |
| 1 Year Change | -34.34% |
| 3 Year Change | -67.01% |
| 5 Year Change | -33.33% |
| Change since IPO | 85.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| MD1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -2.9% | -2.6% |
| 1Y | -34.3% | -8.5% | 6.9% |
Return vs Industry: MD1 underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: MD1 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| MD1 volatility | |
|---|---|
| MD1 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MD1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MD1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 151 | Kari Krogstad | www.medistim.com |
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.
Medistim ASA Fundamentals Summary
| MD1 fundamental statistics | |
|---|---|
| Market cap | €241.70m |
| Earnings (TTM) | €8.60m |
| Revenue (TTM) | €45.84m |
28.1x
P/E Ratio5.3x
P/S RatioIs MD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MD1 income statement (TTM) | |
|---|---|
| Revenue | NOK 541.82m |
| Cost of Revenue | NOK 114.23m |
| Gross Profit | NOK 427.60m |
| Other Expenses | NOK 325.96m |
| Earnings | NOK 101.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 78.92% |
| Net Profit Margin | 18.76% |
| Debt/Equity Ratio | 0% |
How did MD1 perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield81%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medistim ASA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Magnus Granerød | Beringer Finance AB |
| Karl Norén | Danske Bank |
| Simen Mortensen | DNB Markets |